Subscribe
vchal
vchal / iStockphoto.com
11 July 2017Americas

Broad Institute enters talks for CRISPR licensing pool

The Broad Institute of MIT and Harvard has announced that it has entered talks to create a worldwide licensing pool for CRISPR/Cas9 patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sarepta to tap into CRISPR treatment potential
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).
Americas
Broad Institute signs deals to boost medical research
12 October 2017   The Broad Institute of Harvard and MIT has committed itself to tackling complex therapeutic challenges concerning unmet medical needs, while also signing a deal on technology.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Sarepta to tap into CRISPR treatment potential
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).
Americas
Broad Institute signs deals to boost medical research
12 October 2017   The Broad Institute of Harvard and MIT has committed itself to tackling complex therapeutic challenges concerning unmet medical needs, while also signing a deal on technology.

More on this story

Americas
Sarepta to tap into CRISPR treatment potential
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).
Americas
Broad Institute signs deals to boost medical research
12 October 2017   The Broad Institute of Harvard and MIT has committed itself to tackling complex therapeutic challenges concerning unmet medical needs, while also signing a deal on technology.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB